Advanced or Metastatic Gastric Carcinoma, Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer
Conditions
Keywords
Advanced, Metastatic, Hepatocellular cancer, Ovarian cancer, Renal cell cancer, Gastric carcinoma
Brief summary
This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell carcinoma and gastric carcinoma who had progressed after standard therapies.
Detailed description
This was an early stopping design, Phase II, open label, exploratory proof of concept study to evaluate the activity of tasquinimod in four independent cohorts of patients with different tumour types (patients with hepatocellular, ovarian, renal cell or gastric carcinoma, each with progressive disease after standard therapies). Patients initially received 0.5 mg/day tasquinimod dose, increasing to 1 mg/day after at least 2 weeks, unless there were any individual patient safety and tolerability concerns. The treatment period continued until patient disease progression, lost to follow-up, withdrawal or death. During the treatment period, initial study visits were at Week 2, 4 and 8 (± 2 days) for the hepatocellular carcinoma, the ovarian carcinoma and the renal cell carcinoma cohorts and at Week 2, 4 and 6 (± 2 days) for the gastric carcinoma cohort, to allow careful safety monitoring and to facilitate the identification of the individually tolerated dose. After Week 8, when most patients should have reached their tolerable dose, visit frequency was decreased as follows: at Week 16 and 24 (± 2 days) for the hepatocellular carcinoma, the ovarian carcinoma and the renal cell carcinoma cohorts; and at Week 12, 18 and 24 (± 2 days) for the gastric carcinoma cohort. Thereafter visits were once every 8 weeks (± 2 days) for all cohorts. An end of study treatment/withdrawal (EoST/WD) Visit was to be performed at least 14 days after the last dose of study treatment, and/or before treatment with any alternative antitumour therapy was started. Patients who stopped study treatment before disease progression were to be followed up with tumour imaging every 8 weeks until disease progression. Each patient was subsequently followed up for survival (by visit or telephone call) every 3 months after the EoST/WD Visit until death, lost to follow-up, or withdrawal of consent, or until all surviving patients had been followed-up for at least 9 months after their last administration of study treatment. The clinical activity of tasquinimod was evaluated independently in each cohort of patients of the four different tumour types. Data were presented as of the following study cut-off dates: * Hepatocellular carcinoma cohort: 03 December 2014 (efficacy data); 11 April 2016 (safety data). * Ovarian carcinoma cohort: 27 November 2013 (efficacy data); 05 October 2015 (safety data). * Renal cell carcinoma cohort: 04 December 2013. * Gastric carcinoma cohort: 27 September 2013.
Interventions
DRUGTasquinimod
1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
Sponsors
Ipsen
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- All Patients: 1. Able and willing to provide written informed consent and to comply with the study protocol and procedures. 2. Age ≥18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 4. Life expectancy greater than 3 months in the Investigator's opinion. 5. Disease progression during or after previous cancer treatment. 6. Measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria (v1.1). 7. The following time must have elapsed between previous therapy for cancer and first administration of tasquinimod: * At least 2 weeks since previous systemic targeted therapy with small molecule inhibitors, which included any tyrosine-kinase inhibitor. * At least 4 weeks since the last dose of systemic anti-cancer therapy other than targeted therapy, which included cytotoxic agents, monoclonal antibody therapy, immunotherapy and prior radiotherapy. * At least 1 week since prior hormonal therapy. * At least 3 months since prior interferon therapy. 8. Recovery to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies. 9. At least 4 weeks since any major surgery or open biopsy and 7 days since a core biopsy before first study treatment. 10. Adequate renal function: * Creatinine ≤1.5 times upper limit of normal (ULN) or calculated creatinine clearance (CrCl) using the Cockcroft Gault formula ≥60 mL/min, or CrCl ≥60 mL/min. 11. Adequate hepatic function: \- Serum bilirubin ≤1.5 mg/dL (≤25 μmol/L) for ovarian carcinoma, renal cell carcinoma and gastric carcinoma, serum bilirubin ≤3 mg/dL (≤50 μmol/L) for hepatocellular carcinoma cohorts. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (≤5 x ULN if liver lesions were present i.e. liver metastasis or primary tumour of the liver for hepatocellular carcinoma cohort). 12. Adequate bone marrow function: * Absolute neutrophil count (ANC) ≥1.5 x 10\^9/L. * Platelets ≥50 x 10\^9/L. * Haemoglobin ≥90 g/L. 13. Adequate coagulation tests: international normalised ratio (INR) ≤1.5 x ULN. 14. Able to swallow capsules. 15. For women of childbearing potential, a negative pregnancy test must have been documented prior to first administration of study treatment. 16. For women who were not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use adequate methods of contraception (e.g. hormonal implants, combined oral contraceptives, vasectomised partner), during the treatment period and for at least 3 months after the last dose of study treatment. 17. For men: agreement to use a barrier method of contraception during the treatment period and for at least 3 months after the last dose of study treatment. Inclusion Criteria - Hepatocellular Carcinoma Cohort: 18. Histologically confirmed and documented hepatocellular carcinoma (excluding fibrolamellar carcinoma). 19. Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B not amenable to locoregional therapy or refractory to locoregional therapy. 20. Liver mass measuring at least 2 cm with characteristic vascularisation seen on either triphasic computed tomography (CT) scan or Magnetic Resonance Imaging (MRI) with gadolinium. 21. At least one measurable or evaluable lesion that was viable (i.e. vascularised), and had not been previously treated with locoregional therapy. A lesion that had been previously treated qualified as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy. 22. Child-Pugh A Class only. 23. Previously treated with sorafenib. Patients may have experienced radiographically documented disease progression during sorafenib therapy or after discontinuation of sorafenib therapy. 24. The patient had received sorafenib as the most recent systemic therapeutic intervention (any hepatic locoregional therapy that had been administered prior to sorafenib was allowed, but not following sorafenib; radiation to metastatic sites \[e.g. bone\] following sorafenib therapy was permitted). Inclusion Criteria - Ovarian Carcinoma Cohort: 18\. Histologically confirmed and documented ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. 19\. Progression within 6 months of a platinum containing chemotherapy regimen (i.e. platinum resistant). 20\. Progression after up to three lines of chemotherapy. 21\. Maximum one line treatment with antiangiogenic therapy. Inclusion Criteria - Renal Cell Carcinoma Cohort: 18\. Metastatic renal cell carcinoma. 19\. Histologically or cytologically confirmed and documented renal cell carcinoma with a clear cell component. 20\. Previous treatment with at least one vascular endothelial growth factor inhibitor. 21\. Disease progression within 6 months prior to first study treatment. 22\. Patient had at most two prior targeted therapies for unresectable advanced or metastatic disease. Inclusion Criteria - Gastric Carcinoma Cohort: 18\. Histologically or cytologically confirmed and documented adenocarcinoma of the stomach or gastroesophageal junction. 19\. Unresectable advanced or initially metastatic or recurrent after curative resection. 20\. Progression after one prior regimen of chemotherapy including fluoropyrimidine and platinum (with or without trastuzumab, if human epidermal growth factor receptor 2 positive \[HER2+\]). 21\. Maximum one line treatment with antiangiogenic therapy.
Exclusion criteria
- All Patients: 1. Other primary malignancy within the past 3 years (except for fully-resected non-melanoma skin cancer, localised prostate cancer with normal prostate specific antigen level, or cervical cancer in situ). 2. Known central nervous system metastasis that was symptomatic and/or required treatment. 3. Malabsorption (other than in patients with gastric carcinoma and partial or complete gastrectomy) or intestinal obstruction. 4. History of pancreatitis. 5. Essential medications that are known potent inhibitors or inducers of CYP3A4. 6. Ongoing treatment with CYP1A2 (including warfarin) or CYP3A4 metabolised drug substance with narrow therapeutic range at the start of study. Treatment with low molecular weight heparin (LMWH) was permitted. 7. History of myocardial infarction, unstable angina, congestive heart failure New York Heart Association class III/IV, cerebrovascular accident, transient ischaemic attack, limb claudication at rest in the previous 6 months, or ongoing symptomatic dysrhythmias, or uncontrolled atrial, or ventricular arrhythmias, or uncontrolled hypertension defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg. 8. Evidence of bleeding diathesis or known coagulopathy. 9. History of venous thromboembolic disease within 3 months prior to first administration of study treatment. 10. The patient had current, severe and uncontrolled medical condition such as infection, diabetes mellitus or other systemic disease. 11. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would have compromised patient safety or interfered with the evaluation of the safety of the drug. 12. Had known positive serology for human immunodeficiency virus. 13. Investigational drug within 28 days or within five times the elimination half-life (whichever was longest) prior to first dose of study treatment. 14. Known allergy to treatment medication or its excipients. 15. Breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts). | Week 12 (Gastric Carcinoma Cohort); Week 16 (Hepatocellular and Renal Cell Carcinoma Cohorts); Week 24 (Ovarian Carcinoma Cohort). | Progression (prog.) defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in sum of longest diameter of target lesions,or a measurable increase in a nontarget lesion,or appearance of new lesions. 'Progressed or Died' when time between start of study drug &first date of the following events was ≤ to analysis timepoint +3 days:1) Disease prog. according to central review using RECIST v1.1:date of disease prog. or if missing,first exam date of the visit showing a disease prog.2) Death due to any cause. 'Neither progressed, nor died' if central assessment by RECIST v1.1 confirmed no disease prog. was observed at the considered timepoint,i.e. time between start of study medication &last examination/visit date of complete response (CR),partial response (PR) or stable disease (SD) ≥ analysis timepoint 7days.In other cases, such as patient withdrawal due to AEs without tumor assessment proving prog.,the patient was considered as 'not assessable'. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts). | Best overall response was derived as the best overall response documented before the prespecified timepoint (gastric carcinoma cohort: 12 weeks; Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. |
| Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort). | Every 8 weeks until disease progression, up to 36 months. | Per Choi Criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=10% decrease in the sum of the longest diameter of target lesions; Progression, as a 10% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. |
| Clinical Benefit (All Cohorts). | Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts). | Clinical benefit was defined as CR, PR or SD lasting at least 12 weeks using centrally or locally assessed RECIST v1.1. |
| PFS From First Study Treatment to Progression or Death Due to Any Cause Based on Choi Criteria (Hepatocellular Carcinoma Cohort). | Every 8 weeks until disease progression, up to 36 months. | PFS defined as the time from first study treatment to the first occurrence of a disease progression according to centrally assessed Choi criteria (i.e. increase in tumor size ≥10%) or death due to any cause before initiation of new systemic treatment. |
| PFS Rate Measured by Choi Criteria (Hepatocellular Carcinoma Cohort). | Week 16. | PFS rate was defined as the percentage of patients who had neither progressed nor died. Tumour progression was assessed centrally using the Choi criteria. Response was measured using the following criteria: CR: Disappearance of all lesions, no new lesions; PR: A decrease in size ≥10% or a decrease in tumour attenuation (Hounsfield unit \[HU\]) ≥15% on CT, no new lesions, no obvious progression of non-measurable disease; SD: Does not meet criteria for CR, PR, or progressive disease (PD), no symptomatic deterioration attributed to tumour progression; PD: An increase in tumour size ≥10% and does not meet criteria of PR by tumour attenuation on CT, new lesions. |
| Time to Progression (TTP) by Choi Criteria (Hepatocellular Carcinoma Cohort). | Every 8 weeks until disease progression, up to 36 months. | TTP defined as the time from first study treatment to the first occurrence of disease progression defined according to centrally assessed Choi criteria (i.e. increase in tumor size ≥10%) or death due to disease progression before initiation of a new systemic treatment. |
| TTP by RECIST v1.1 (All Cohorts). | Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts). | TTP was defined as the time from first study treatment to the first occurrence of disease progression defined according to centrally and locally assessed RECIST v1.1 criteria (i.e. increase in tumor size ≥20%) or death due to disease progression before initiation of a new systemic treatment. |
| Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts). | Time from first study treatment to death, up to 36 months. | OS is the time (in weeks) from the first study medication date to death due to any cause. Patients were censored at the date of last contact (the latest between the time of EoST/WD assessment and follow-up visits). OS was estimated using Kaplan-Meier analysis. |
| Further Cancer-related Treatment During Follow-up Period (All Cohorts). | 16 weeks, Last Patient First Treatment + 16 weeks. | Further systemic treatment was coded using World Health Organization (WHO) Drug Dictionary (versions: June 2014 for the hepatocellular carcinoma cohort and June 2013 for the ovarian, renal cell and gastric carcinoma cohorts). A frequency table of the number and percentage of patients was provided by Anatomical Therapeutic Chemical (ATC) decode and preferred name. |
| PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts). | PFS defined as the time from first study treatment to the first occurrence of a disease progression according to centrally and locally assessed RECIST v1.1 (i.e. increase in tumor size ≥20%) or death due to any cause before initiation of new systemic treatment. |
Countries
Belgium, Canada, France, Spain, United Kingdom
Participant flow
Recruitment details
Patients were recruited from 24 investigational sites in Belgium, Canada, the United Kingdom, Spain and France. The first patient was enrolled in December 2012 and the study was completed in April 2016.
Pre-assignment details
In the hepatocellular carcinoma cohort 67 patients were screened, of whom 53 were treated with tasquinimod. In the ovarian carcinoma cohort 63 were screened, of whom 55 were treated. In the renal cell carcinoma cohort 44 were screened, of whom 38 were treated. In the gastric carcinoma cohort 27 were screened, of whom 21 were treated.
Participants by arm
| Arm | Count |
|---|---|
| Hepatocellular Carcinoma Cohort 1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
Tasquinimod: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks. | 53 |
| Ovarian Carcinoma Cohort 1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
Tasquinimod: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks. | 55 |
| Renal Cell Carcinoma Cohort 1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
Tasquinimod: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks. | 38 |
| Gastric Carcinoma Cohort 1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
Tasquinimod: 1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks. | 21 |
| Total | 167 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Active Treatment Phase | Adverse Event | 10 | 5 | 8 | 1 |
| Active Treatment Phase | Disease Progression | 40 | 47 | 30 | 20 |
| Active Treatment Phase | Missing | 1 | 0 | 0 | 0 |
| Active Treatment Phase | Withdrawal by Subject | 2 | 3 | 0 | 0 |
| Follow-up Period - Post-Treatment | Death | 43 | 47 | 22 | 16 |
| Follow-up Period - Post-Treatment | Lost to Follow-up | 1 | 1 | 0 | 0 |
| Follow-up Period - Post-Treatment | Withdrawal by Subject | 1 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Hepatocellular Carcinoma Cohort | Ovarian Carcinoma Cohort | Renal Cell Carcinoma Cohort | Gastric Carcinoma Cohort | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 34 Participants | 21 Participants | 13 Participants | 10 Participants | 78 Participants |
| Age, Categorical Between 18 and 65 years | 19 Participants | 34 Participants | 25 Participants | 11 Participants | 89 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 33 Participants | 53 Participants | 33 Participants | 19 Participants | 138 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 19 Participants | 2 Participants | 4 Participants | 2 Participants | 27 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants | 2 Participants | 0 Participants | 2 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 19 Participants | 2 Participants | 3 Participants | 2 Participants | 26 Participants |
| Race (NIH/OMB) White | 29 Participants | 49 Participants | 35 Participants | 17 Participants | 130 Participants |
| Region of Enrollment Belgium | 3 Participants | 10 Participants | 0 Participants | 2 Participants | 15 Participants |
| Region of Enrollment Canada | 3 Participants | 22 Participants | 9 Participants | 4 Participants | 38 Participants |
| Region of Enrollment France | 43 Participants | 9 Participants | 12 Participants | 2 Participants | 66 Participants |
| Region of Enrollment Spain | 1 Participants | 3 Participants | 3 Participants | 0 Participants | 7 Participants |
| Region of Enrollment United Kingdom | 3 Participants | 11 Participants | 14 Participants | 13 Participants | 41 Participants |
| Sex: Female, Male Female | 8 Participants | 55 Participants | 10 Participants | 4 Participants | 77 Participants |
| Sex: Female, Male Male | 45 Participants | 0 Participants | 28 Participants | 17 Participants | 90 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 38 / 53 | 22 / 55 | 22 / 38 | 16 / 21 |
| other Total, other adverse events | 53 / 53 | 55 / 55 | 38 / 38 | 21 / 21 |
| serious Total, serious adverse events | 14 / 53 | 19 / 55 | 11 / 38 | 7 / 21 |
Outcome results
Primary
Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts).
Progression (prog.) defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in sum of longest diameter of target lesions,or a measurable increase in a nontarget lesion,or appearance of new lesions. 'Progressed or Died' when time between start of study drug &first date of the following events was ≤ to analysis timepoint +3 days:1) Disease prog. according to central review using RECIST v1.1:date of disease prog. or if missing,first exam date of the visit showing a disease prog.2) Death due to any cause. 'Neither progressed, nor died' if central assessment by RECIST v1.1 confirmed no disease prog. was observed at the considered timepoint,i.e. time between start of study medication &last examination/visit date of complete response (CR),partial response (PR) or stable disease (SD) ≥ analysis timepoint 7days.In other cases, such as patient withdrawal due to AEs without tumor assessment proving prog.,the patient was considered as 'not assessable'.
Time frame: Week 12 (Gastric Carcinoma Cohort); Week 16 (Hepatocellular and Renal Cell Carcinoma Cohorts); Week 24 (Ovarian Carcinoma Cohort).
Population: ITT population: All treated patients i.e. all patients who had received at least one dose of tasquinimod. An additional patient was included in the hepatocellular carcinoma cohort, since the 52nd (last patient planned in the protocol) and 53rd were screened at the same time. This 53rd was not included in the primary analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hepatocellular Carcinoma Cohort | Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts). | 26.9 percentage of participants |
| Ovarian Carcinoma Cohort | Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts). | 7.3 percentage of participants |
| Renal Cell Carcinoma Cohort | Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts). | 13.2 percentage of participants |
| Gastric Carcinoma Cohort | Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All Cohorts). | 9.5 percentage of participants |
Comparison: The PFS rate was compared with the prespecified threshold (\>20%).p-value: 0.142Exact binomial test
Comparison: The PFS rate was compared with the prespecified threshold (\>35%).p-value: 1Exact binomial test
Comparison: The PFS rate was compared with the prespecified threshold (\>20%).p-value: 0.8Exact binomial test
Comparison: The PFS rate was compared with the prespecified threshold (\>15%).p-value: 0.63Exact binomial test
Secondary
Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort).
Per Choi Criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=10% decrease in the sum of the longest diameter of target lesions; Progression, as a 10% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.
Time frame: Every 8 weeks until disease progression, up to 36 months.
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort). | Best overall response: PR | 20.8 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort). | Best overall response: SD | 32.1 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort). | Best overall response: PD | 34.0 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort). | Best overall response: NE | 13.2 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rate Based on Choi Criteria (Hepatocellular Carcinoma Cohort). | Response rate (CR or PR) | 20.8 percentage of participants |
Secondary
Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed).
Best overall response was derived as the best overall response documented before the prespecified timepoint (gastric carcinoma cohort: 12 weeks; Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a nontarget lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.
Time frame: Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).
Population: ITT population: all treated patients i.e. all patients who had received at lease one dose of tasquinimod.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PD (locally assessed) | 43.4 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: SD (centrally assessed) | 54.7 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Response rate (CR or PR) (centrally assessed) | 1.9 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: NE (centrally assessed) | 9.4 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PD (centrally assessed) | 34.0 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PR (centrally assessed) | 1.9 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Response rate (CR or PR) (locally assessed) | 0 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: NE (locally assessed) | 3.8 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: SD (locally assessed) | 52.8 percentage of participants |
| Hepatocellular Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PR (locally assessed) | 0 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PD (locally assessed) | 61.8 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PR (centrally assessed) | 1.8 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: NE (locally assessed) | 5.5 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Response rate (CR or PR) (locally assessed) | 0 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PD (centrally assessed) | 41.8 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: NE (centrally assessed) | 7.3 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Response rate (CR or PR) (centrally assessed) | 1.8 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PR (locally assessed) | 0 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: SD (centrally assessed) | 49.1 percentage of participants |
| Ovarian Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: SD (locally assessed) | 32.7 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PD (centrally assessed) | 44.7 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: NE (locally assessed) | 2.6 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: SD (locally assessed) | 39.5 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PR (locally assessed) | 0 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: SD (centrally assessed) | 47.4 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Response rate (CR or PR) (locally assessed) | 0 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: NE (centrally assessed) | 7.9 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PR (centrally assessed) | 0 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PD (locally assessed) | 57.9 percentage of participants |
| Renal Cell Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Response rate (CR or PR) (centrally assessed) | 0 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Response rate (CR or PR) (locally assessed) | 0 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PR (centrally assessed) | 0 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: SD (centrally assessed) | 23.8 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PD (centrally assessed) | 66.7 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: NE (centrally assessed) | 9.5 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Response rate (CR or PR) (centrally assessed) | 0 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PR (locally assessed) | 0 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: SD (locally assessed) | 14.3 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: PD (locally assessed) | 81.0 percentage of participants |
| Gastric Carcinoma Cohort | Best Overall Response and Response Rates (All Cohorts) Using RECIST v1.1 (Centrally and Locally Analysed). | Best overall response: NE (locally assessed) | 4.8 percentage of participants |
Secondary
Clinical Benefit (All Cohorts).
Clinical benefit was defined as CR, PR or SD lasting at least 12 weeks using centrally or locally assessed RECIST v1.1.
Time frame: Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Hepatocellular Carcinoma Cohort | Clinical Benefit (All Cohorts). | Clinical benefit (centrally assessed) | 26.4 percentage of participants |
| Hepatocellular Carcinoma Cohort | Clinical Benefit (All Cohorts). | Clinical benefit (locally assessed) | 32.1 percentage of participants |
| Ovarian Carcinoma Cohort | Clinical Benefit (All Cohorts). | Clinical benefit (locally assessed) | 16.4 percentage of participants |
| Ovarian Carcinoma Cohort | Clinical Benefit (All Cohorts). | Clinical benefit (centrally assessed) | 20.0 percentage of participants |
| Renal Cell Carcinoma Cohort | Clinical Benefit (All Cohorts). | Clinical benefit (centrally assessed) | 15.8 percentage of participants |
| Renal Cell Carcinoma Cohort | Clinical Benefit (All Cohorts). | Clinical benefit (locally assessed) | 15.8 percentage of participants |
| Gastric Carcinoma Cohort | Clinical Benefit (All Cohorts). | Clinical benefit (centrally assessed) | 0.0 percentage of participants |
| Gastric Carcinoma Cohort | Clinical Benefit (All Cohorts). | Clinical benefit (locally assessed) | 0.0 percentage of participants |
Secondary
Further Cancer-related Treatment During Follow-up Period (All Cohorts).
Further systemic treatment was coded using World Health Organization (WHO) Drug Dictionary (versions: June 2014 for the hepatocellular carcinoma cohort and June 2013 for the ovarian, renal cell and gastric carcinoma cohorts). A frequency table of the number and percentage of patients was provided by Anatomical Therapeutic Chemical (ATC) decode and preferred name.
Time frame: 16 weeks, Last Patient First Treatment + 16 weeks.
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Hepatocellular Carcinoma Cohort | Further Cancer-related Treatment During Follow-up Period (All Cohorts). | 16 Participants |
| Ovarian Carcinoma Cohort | Further Cancer-related Treatment During Follow-up Period (All Cohorts). | 35 Participants |
| Renal Cell Carcinoma Cohort | Further Cancer-related Treatment During Follow-up Period (All Cohorts). | 18 Participants |
| Gastric Carcinoma Cohort | Further Cancer-related Treatment During Follow-up Period (All Cohorts). | 8 Participants |
Secondary
Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts).
OS is the time (in weeks) from the first study medication date to death due to any cause. Patients were censored at the date of last contact (the latest between the time of EoST/WD assessment and follow-up visits). OS was estimated using Kaplan-Meier analysis.
Time frame: Time from first study treatment to death, up to 36 months.
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Hepatocellular Carcinoma Cohort | Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts). | 29.29 Weeks |
| Ovarian Carcinoma Cohort | Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts). | NA Weeks |
| Renal Cell Carcinoma Cohort | Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts). | 32.71 Weeks |
| Gastric Carcinoma Cohort | Overall Survival (OS), Defined as the Time From First Study Treatment to Death Due to Any Cause (All Cohorts). | 21.57 Weeks |
Secondary
PFS From First Study Treatment to Progression or Death Due to Any Cause Based on Choi Criteria (Hepatocellular Carcinoma Cohort).
PFS defined as the time from first study treatment to the first occurrence of a disease progression according to centrally assessed Choi criteria (i.e. increase in tumor size ≥10%) or death due to any cause before initiation of new systemic treatment.
Time frame: Every 8 weeks until disease progression, up to 36 months.
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Hepatocellular Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on Choi Criteria (Hepatocellular Carcinoma Cohort). | 15.71 Weeks |
Secondary
PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts).
PFS defined as the time from first study treatment to the first occurrence of a disease progression according to centrally and locally assessed RECIST v1.1 (i.e. increase in tumor size ≥20%) or death due to any cause before initiation of new systemic treatment.
Time frame: Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Hepatocellular Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | PFS (centrally assessed) | 15.86 Weeks |
| Hepatocellular Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | PFS (locally assessed) | 15.71 Weeks |
| Ovarian Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | PFS (locally assessed) | 7.57 Weeks |
| Ovarian Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | PFS (centrally assessed) | 8.00 Weeks |
| Renal Cell Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | PFS (centrally assessed) | 14.86 Weeks |
| Renal Cell Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | PFS (locally assessed) | 7.86 Weeks |
| Gastric Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | PFS (centrally assessed) | 6.00 Weeks |
| Gastric Carcinoma Cohort | PFS From First Study Treatment to Progression or Death Due to Any Cause Based on RECIST v1.1 Criteria (All Cohorts). | PFS (locally assessed) | 5.79 Weeks |
Secondary
PFS Rate Measured by Choi Criteria (Hepatocellular Carcinoma Cohort).
PFS rate was defined as the percentage of patients who had neither progressed nor died. Tumour progression was assessed centrally using the Choi criteria. Response was measured using the following criteria: CR: Disappearance of all lesions, no new lesions; PR: A decrease in size ≥10% or a decrease in tumour attenuation (Hounsfield unit \[HU\]) ≥15% on CT, no new lesions, no obvious progression of non-measurable disease; SD: Does not meet criteria for CR, PR, or progressive disease (PD), no symptomatic deterioration attributed to tumour progression; PD: An increase in tumour size ≥10% and does not meet criteria of PR by tumour attenuation on CT, new lesions.
Time frame: Week 16.
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hepatocellular Carcinoma Cohort | PFS Rate Measured by Choi Criteria (Hepatocellular Carcinoma Cohort). | 20.8 percentage of participants |
Comparison: The PFS rate was compared with a prespecified threshold (\>20%).p-value: 0.5Exact binomial test
Secondary
Time to Progression (TTP) by Choi Criteria (Hepatocellular Carcinoma Cohort).
TTP defined as the time from first study treatment to the first occurrence of disease progression defined according to centrally assessed Choi criteria (i.e. increase in tumor size ≥10%) or death due to disease progression before initiation of a new systemic treatment.
Time frame: Every 8 weeks until disease progression, up to 36 months.
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Hepatocellular Carcinoma Cohort | Time to Progression (TTP) by Choi Criteria (Hepatocellular Carcinoma Cohort). | 15.86 Weeks |
Secondary
TTP by RECIST v1.1 (All Cohorts).
TTP was defined as the time from first study treatment to the first occurrence of disease progression defined according to centrally and locally assessed RECIST v1.1 criteria (i.e. increase in tumor size ≥20%) or death due to disease progression before initiation of a new systemic treatment.
Time frame: Every 6 weeks until Week 24, thereafter, every 8 weeks until disease progression, up to 36 months (gastric carcinoma cohort); every 8 weeks until disease progression, up to 36 months (all other cohorts).
Population: ITT population: all treated patients i.e. all patients who had received at least one dose of tasquinimod.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Hepatocellular Carcinoma Cohort | TTP by RECIST v1.1 (All Cohorts). | TTP (centrally assessed) | 15.86 Weeks |
| Hepatocellular Carcinoma Cohort | TTP by RECIST v1.1 (All Cohorts). | TTP (locally assessed) | 15.71 Weeks |
| Ovarian Carcinoma Cohort | TTP by RECIST v1.1 (All Cohorts). | TTP (locally assessed) | 7.57 Weeks |
| Ovarian Carcinoma Cohort | TTP by RECIST v1.1 (All Cohorts). | TTP (centrally assessed) | 8.00 Weeks |
| Renal Cell Carcinoma Cohort | TTP by RECIST v1.1 (All Cohorts). | TTP (centrally assessed) | 14.86 Weeks |
| Renal Cell Carcinoma Cohort | TTP by RECIST v1.1 (All Cohorts). | TTP (locally assessed) | 7.86 Weeks |
| Gastric Carcinoma Cohort | TTP by RECIST v1.1 (All Cohorts). | TTP (centrally assessed) | 6.00 Weeks |
| Gastric Carcinoma Cohort | TTP by RECIST v1.1 (All Cohorts). | TTP (locally assessed) | 5.79 Weeks |